Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance)

被引：0
|
作者：
Shih, J. Y.
Goldstein, L. J.
机构：
来源：
Breast Diseases | 2015年 / 26卷 / 01期
关键词：
D O I：
10.1016/j.breastdis.2015.01.015
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页码：83 / 84
页数：3
相关论文
共 50 条
  • [1] Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance)
    Shulman, Lawrence N.
    Berry, Donald A.
    Cirrincione, Constance T.
    Becker, Heather P.
    Perez, Edith A.
    O'Regan, Ruth
    Martino, Silvana
    Shapiro, Charles L.
    Schneider, Charles J.
    Kimmick, Gretchen
    Burstein, Harold J.
    Norton, Larry
    Muss, Hyman
    Hudis, Clifford A.
    Winer, Eric P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (22) : 2311 - U184
  • [2] Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101
    Shulman, Lawrence N.
    Berry, Donald A.
    Cirrincione, Constance T.
    Becker, Heather
    Perez, Edith A.
    O'Regan, Ruth
    Martino, Silvana
    Shapiro, Charles L.
    Atkins, James
    Schneider, Charles
    Kimmick, Gretchen Genevieve
    Burstein, Harold J.
    Norton, Larry
    Musa, Hyman Bernard
    Hudis, Clifford
    Winer, Eric P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101
    Shulman, Lawrence N.
    Cirrincione, Constance T.
    Berry, Donald A.
    Becker, Heather P.
    Perez, Edith A.
    O'Regan, Ruth
    Martino, Silvana
    Atkins, James N.
    Mayer, Erica
    Schneider, Charles J.
    Kimmick, Gretchen
    Norton, Larry
    Muss, Hyman
    Winer, Eric P.
    Hudis, Clifford
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (33) : 4071 - 4076
  • [4] Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes
    Hudis, CA
    Seidman, AD
    Baselga, J
    Raptis, G
    Lebwohl, D
    Gilewski, T
    Currie, V
    Moynahan, ME
    Sklarin, N
    Fennelly, D
    Uhlenhopp, M
    Riedel, E
    Yao, TJ
    Norton, L
    [J]. SEMINARS IN ONCOLOGY, 1995, 22 (06) : 18 - 23
  • [5] Four vs 6 Cycles of Doxorubicin and Cyclophosphamide (AC) or Paclitaxel (T) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Nodes: CALGB 40101-A 2x2 Factorial Phase III Trial: First Results Comparing 4 vs 6 Cycles of Therapy
    Shulman, L. N.
    Cirrincione, C.
    Berry, D. A.
    Becker, H. P.
    Perez, E.
    O'Regan, R.
    Martino, S.
    Atkins, J. N.
    Hudis, C.
    Winer, E.
    [J]. CANCER RESEARCH, 2010, 70
  • [6] Comparison of six cycles of epirubicin and paclitaxel (ET) versus four cycles of epirubicin and cyclophosphamide, followed by four cycles of paclitaxel (EC-T) as adjuvant therapy for operable breast cancer in women with positive axillary nodes
    Yuan, Peng
    Wang, Jiayu
    Ma, Fei
    Fan, Ying
    Luo, Yang
    Cai, Ruigang
    Zhang, Pin
    Li, Qing
    Xu, Binghe
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL WITH AND WITHOUT DOXORUBICIN IN THE ADJUVANT TREATMENT OF RESECTABLE BREAST-CANCER WITH ONE TO 3 POSITIVE AXILLARY NODES
    MOLITERNI, A
    BONADONNA, G
    VALAGUSSA, P
    FERRARI, L
    ZAMBETTI, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (07) : 1124 - 1130
  • [8] ADJUVANT CHEMOTHERAPY WITH DOXORUBICIN PLUS CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL IN THE TREATMENT OF RESECTABLE BREAST-CANCER WITH MORE THAN 3 POSITIVE AXILLARY NODES
    BUZZONI, R
    BONADONNA, G
    VALAGUSSA, P
    ZAMBETTI, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (12) : 2134 - 2140
  • [9] Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial
    Parmar, MKB
    Adams, M
    Balestrino, M
    Bertelsen, K
    Bonazzi, C
    Calvert, H
    Colombo, N
    Delaloye, JF
    Durando, A
    Guthrie, D
    Hagen, B
    Harper, P
    Mangioni, C
    Perren, T
    Poole, C
    Qian, W
    Rustin, G
    Sandercock, J
    Tumolo, S
    Torri, V
    Vecchione, F
    [J]. LANCET, 2002, 360 (9332): : 505 - 515
  • [10] ADJUVANT RANDOMIZED TRIALS OF DOXORUBICIN CYCLOPHOSPHAMIDE VERSUS DOXORUBICIN CYCLOPHOSPHAMIDE TAMOXIFEN AND CMF CHEMOTHERAPY VERSUS TAMOXIFEN IN WOMEN WITH NODE-POSITIVE BREAST-CANCER
    KAUFMANN, M
    JONAT, W
    ABEL, U
    HILFRICH, J
    CAFFIER, H
    KREIENBERG, R
    TRAMS, G
    BRUNNERT, K
    SCHERMANN, J
    KLEINE, W
    MAHLKE, M
    NEISES, M
    STOSIEK, U
    STIGLMAYER, R
    SEEGER, F
    LANGNICKEL, D
    NAGEL, G
    GAMPE, M
    MAASS, H
    KUBLI, F
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) : 454 - 460
12345